Product Images Tadalafil

This appears to be a table displaying blood pressure measurements of individuals taking either tadalafil or placebo medication while standing and lying down. The table shows the difference in systolic and diastolic blood pressure between the two groups in millimeters of mercury (mmHg). However, without more context or information, it is difficult to provide a more detailed description or interpretation of the data.*

This appears to be a graph or chart displaying the standing and supine systolic blood pressure (BP) in mmHg for patients taking Tadalafil 20 mg & doxazosin 8 mg or placebo & doxazosin 8 mg over a period of 24 hours, with time post-dose (in hours) on the x-axis.*

The text shows a chart with systolic blood pressure readings (measured in mmHg) at different times after taking either a combination of 20 mg tadalafil and 8 mg doxazosin or placebo with 8 mg doxazosin. The readings were taken at 8:00 and 20:00. The chart contains symbols such as +, -, e, and v to represent the readings. The time after administration of the medication is also specified.*

This is a graph showing the concentration of Tadalafil in plasma, measured in micrograms per liter (ug/L), over a period of 120 hours (5 days). The graph compares the concentration levels of a single 20-mg dose of Tadalafil, a single 5-mg dose of Tadalafil, and a once-daily 5-mg dose of Tadalafil administered for 5 consecutive days. The concentration levels are shown to peak around 2 hours after administration and gradually decrease over time.*

The text reports the change from baseline in PSS (Perceived Stress Scale) Total Score for Tadalafil 5mg compared to Placebo. A statistically significant difference is indicated with *p<0.01. The duration of treatment is shown in weeks.*

The text shows the result of a clinical study comparing the efficacy of Tadalafil 5mg versus a placebo in reducing IPSS Total Score. The result shows a statistically significant difference between the two groups (p<0.01). However, there is no information about the duration of the study or the condition being treated.*

This appears to be a table or chart showing the "LS Mean Change from Baseline" for two treatments: "TadalafilFinasteride" and "Placebo/Finasteride" over a span of "Weeks of Therapy" at 4, 12, and 26 weeks. However, without additional context or values, it is difficult to provide a specific description of what the data represents or measures.*

This is a graph that shows the change in the International Prostate Symptom Score (IPSS) total score between a placebo group and a group receiving 5mg of Tadalafil. The study lasted for several weeks and the data indicates that Tadalafil had a statistically significant effect in reducing IPSS score.*

This is a description of Tadalafil Tablets, USP, containing 25mg of the medicine. The package contains 30 tablets that should not be split, and the entire dose should be taken. The usual dosage information is available in the package insert. The tablets should be stored in a container at a temperature range of 20°C to 25°C. The medicine should be kept out of the reach of children. It is manufactured by Catla Healthcare L in Anmedzbad, nde and distributed by Zydus Pharmaceuticals (USA) Inc. in Pemingion, NJ 08534.*

This is the description for Tadalafil Tablets, USP. These tablets contain 5mg of Tadalafil, USP and should not be split. The full dose should be taken and it is advisable to see the package insert for precise dosing information. The tablets are film-coated and come in a package of 30 tablets. They should be stored at a temperature between 20°to 25°C (68°t0 77°F) and dispensed in a tight container. The drug is manufactured by Cada Healthcare Ld in Ahmedabad, India, and distributed in the USA by Zydus Pharmaceuticals (USA) Inc. Code No: GUJIDRUGI1485.*

This appears to be a medication label for Tadalafil tablets, USP, distributed by AYDUS Pharmaceuticals (USA) Inc. The recommended storage temperature is between 20-25°C and the tablets should be dispensed in a tight container. The label also includes a code number and cautions to keep the drug out of reach of children. The manufacturer is listed as Cadla Healthcare Ld. It is not clear what the text "No Vanished Area (Do Not Prin) (18 x 41 mm)" refers to.*

This is a prescription drug label for Tadalafil tablets with a strength of Mgt. It provides the NDC code, storage instructions, and a caution to keep it out of reach of children. The drug is manufactured by Zydus and should not be split.*